This is a StreetInsider.com Premium Only Page

HUTCHMED (China) (HCM) – StreetInsider.com Reports

Feb 2, 2024 09:03 AM Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED (HCM)

Jan 30, 2024 05:49 AM HUTCHMED (China) (HCM) Receives ELUNATE Marketing Approval in Hong Kong

Nov 24, 2023 04:17 AM Deutsche Bank Upgrades Hutchison China MediTech Ltd. (HCM) to Buy, 'Opening up overseas market'

Nov 10, 2023 05:58 AM Hutchison China MediTech Ltd. (HCM) PT Raised to $17 at Goldman Sachs

Jul 31, 2023 07:51 AM Hutchison China MediTech (HCM) Tops Q2 EPS by 103c

Jul 31, 2023 07:42 AM HUTCHMED (China) (HCM) Reports 2023 Interim Results; Provides Business Updates

Jun 16, 2023 06:00 AM Takeda Pharmaceutical (TAK) and HUTCHMED (HCM) Announce Publication of Phase 3 FRESCO-2 Results

May 25, 2023 04:31 PM Takeda Pharmaceutical (TAK) and HUTCHMED (HCM) Announce New Drug Application (NDA) for Fruquintinib

Apr 18, 2023 05:49 AM HUTCHMED (China) (HCM) Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

Mar 31, 2023 05:49 AM HUTCHMED (China) (HCM) Completes Rolling Submission of NDA to FDA for Fruquintinib

Mar 13, 2023 05:55 AM HUTCHMED (China) (HCM) Confirms No Assets Held at Silicon Valley Bank

Feb 28, 2023 05:51 AM HUTCHMED (China) (HCM) Reports FY22, Issues Business Update

Jan 23, 2023 05:46 AM HUTCHMED (China) (HCM) Sells License for Fruquintinib Outside China to Takeda (TAK)

Jan 18, 2023 09:30 AM HUTCHMED (China) (HCM) Announces Agreement with NHSA for Inclusion of ORPATHYS to the National Reimbursement Drug List in China

Dec 19, 2022 05:16 AM HUTCHMED (China) (HCM) Initiates Rolling NDA Submission for Fruquintinib for the Treatment of Refractory Colorectal Cancer

Nov 15, 2022 05:39 AM HUTCHMED (China) (HCM) Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

Nov 14, 2022 05:49 AM HUTCHMED (HCM) Reports Positive Topline Result in Fruquintinib Phase III FRUTIGA Study

Oct 24, 2022 10:53 AM HUTCHMED (China) (HCM) 30-day option implied at 65 as shares sell off 14%

Aug 23, 2022 06:11 AM HUTCHMED (China) (HCM) to Present Additional Fruquintinib MRCT FRESCO-2 Data

Aug 8, 2022 11:29 AM Hutchison China MediTech Ltd. (HCM) PT Raised to $16 at Goldman Sachs

Aug 8, 2022 05:49 AM HUTCHMED (China) (HCM) Reports Phase III FRESCO-2 Study Has Met Its Primary Endpoint

Aug 1, 2022 07:08 AM Hutchison China MediTech (HCM) Reports 1st-Half Loss of $0.19

Aug 1, 2022 07:01 AM HUTCHMED (China) (HCM) Reports 2022 Interim Results and Provides Business Updates

Jul 15, 2022 06:05 AM HUTCHMED (China) (HCM) Commences Phase I Trial of HMPL-A83

Jul 13, 2022 06:36 AM Latest Hutchinson (HCM) Data "Underscores Belief HCM's Pipeline is Underappreciated" - Cantor Fitzgerald Reiterates Overweight and $50 Price Target

Jun 1, 2022 05:52 AM HUTCHMED (China) (HCM) Announces TAZVERIK Approved for Use in Hainan Pilot Zone in China

May 4, 2022 12:21 PM Deutsche Bank Downgrades Hutchison China MediTech Ltd. (HCM) to Hold

May 3, 2022 08:09 AM Hutchison China MediTech Ltd. (HCM) PT Lowered to $17 at Goldman Sachs

May 3, 2022 05:55 AM Hutchison China MediTech Ltd. (HCM) PT Lowered to $22 at BofA Securities

May 2, 2022 06:00 AM HUTCHMED (China) (HCM) Receives CRL for Surufatinib for Treatment of Advanced Neuroendocrine

Mar 30, 2022 01:01 PM Baidu (BIDU) Becomes Largest Chinese Stock Added to SEC's HFCAA List

Mar 28, 2022 11:10 AM UPDATE: HUTCHMED (China) (HCM) and Viatris (VTRS) Top Cantor Fitzgerald's List of Biggest Short Interest Increases, Heron (HRTX) and Omeros (OMER) Continue to Have Higher Short Floats

Mar 16, 2022 04:17 AM HUTCHMED (China) (HCM) 30-day option implied volatility at 91

Mar 14, 2022 05:07 AM HUTCHMED (China) (HCM) 30-day option implied volatility at 102

Mar 11, 2022 11:05 AM HUTCHMED (China) (HCM) option implied volatility elevated as shares sell off 7.9%

Mar 11, 2022 05:42 AM HUTCHMED (China) (HCM) Provides Update on Status under Holding Foreign Companies Accountable Act

Mar 11, 2022 04:28 AM HUTCHMED (China) (HCM) option implied volatility elevated

Mar 10, 2022 12:38 PM HUTCHMED (China) (HCM) call put ratio 13 calls to 1 put as shares sell off 4.4%

Mar 10, 2022 12:27 PM BGNE, YUMC, ZLAB, ACMR, HCM Slammed as Stocks Identified Under HFCAA for Delisting

Mar 10, 2022 12:22 PM UPDATE: Decline in JD.com (JD) and Alibaba (BABA) appears related to naming of first 5 Chinese ADR's under HFCAA - CNBC

Mar 7, 2022 05:45 AM HUTCHMED (China) (HCM) Receives $15M Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS in Lung Cancer

Mar 3, 2022 02:53 PM Cantor Fitzgerald Reiterates Hutchison China MediTech Ltd. (HCM) at Overweight, Believes HCM's Pipeline is Underappreciated

Mar 3, 2022 07:33 AM HUTCHMED (China) (HCM) Announces CEO Retirement, Appoints Weiguo Su as New CEO

Mar 1, 2022 05:52 AM HUTCHMED (China) (HCM) Announces Approval to Commercialize ELUNATE in Macau

Feb 16, 2022 07:23 AM Hutchison China MediTech Ltd. (HCM) PT Lowered to $41 at Goldman Sachs

Feb 10, 2022 04:25 AM Genetron (GTH) Enters Collaboration Agreement with HUTCHMED’s (HCM) ORPATHYS for NSCLC

Feb 4, 2022 05:32 AM HUTCHMED (China) (HCM) Commences Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab

Jan 20, 2022 05:39 AM HUTCHMED (China) (HCM) Commences Phase I Trial of HMPL-653

Jan 12, 2022 06:00 AM HUTCHMED (China) (HCM) Granted Breakthrough Therapy Designation in China for HMPL-523

Dec 20, 2021 05:42 AM HUTCHMED (China) (HCM) Added to FTSE Russell Indexes